Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price ...

AstraZeneca plc shares are trading slightly higher on the London Stock Exchange after a 3.1% gain in the US market on 06/04/2026, while investors reassess valuation metrics and growth prospects ...

AstraZenecaâ s (LSE: AZN) share price looks to me to be anchored to an outdated view of its long-term earnings potential. This appears to reflect a mature, late-cycle pharmaceutical firm reliant on a ...

AstraZeneca (LSE:AZN) moved into focus after announcing an AI and cloud partnership with Oracle aimed at speeding clinical ...

LONDON, July 24 (Reuters) - ⁠AstraZeneca's ⁠long-time CEO Pascal Soriot has rarely put a ⁠foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above ...

AstraZeneca PLC (AZN), the Cambridge, United Kingdom-headquartered Pharma giant with a market cap valuation just shy of $300bn at the time of writing (source: TradingView), announced its Q4 and ...

AstraZeneca PLC updated its London share count and total voting rights going into Tuesday trading, while the NYSE-listed stock trades lower after a 3.2% drop to USD 179.71 on 06/01/2026, keeping the ...

AstraZeneca PLC (NASDAQ:AZN | AZN Price Prediction) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date, the stock has gained 6.02%, though it has pulled ...

Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance.

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale More than £17bn was wiped off the value of Britain’s biggest drugmaker, ...